Could KL-6 levels in COVID-19 help to predict lung disease?
Biomarker
COVID-19
Interstitial lung disease
KL-6
Lung infection
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
24 Nov 2020
24 Nov 2020
Historique:
received:
18
05
2020
accepted:
29
10
2020
entrez:
25
11
2020
pubmed:
26
11
2020
medline:
16
1
2021
Statut:
epublish
Résumé
Coronavirus disease COVID-19 has become a public health emergency of international concern. Together with the quest for an effective treatment, the question of the post-infectious evolution of affected patients in healing process remains uncertain. Krebs von den Lungen 6 (KL-6) is a high molecular weight mucin-like glycoprotein produced by type II pneumocytes and bronchial epithelial cells. Its production is raised during epithelial lesions and cellular regeneration. In COVID-19 infection, KL-6 serum levels could therefore be of interest for diagnosis, prognosis and therapeutic response evaluation. Our study retrospectively compared KL-6 levels between a cohort of 83 COVID-19 infected patients and two other groups: healthy subjects (n = 70) on one hand, and a heterogenous group of patients suffering from interstitial lung diseases (n = 31; composed of 16 IPF, 4 sarcoidosis, 11 others) on the other hand. Demographical, clinical and laboratory indexes were collected. Our study aims to compare KL-6 levels between a COVID-19 population and healthy subjects or patients suffering from interstitial lung diseases (ILDs). Ultimately, we ought to determine whether KL-6 could be a marker of disease severity and bad prognosis. Our results showed that serum KL-6 levels in COVID-19 patients were increased compared to healthy subjects, but to a lesser extent than in patients suffering from ILD. Increased levels of KL-6 in COVID-19 patients were associated with a more severe lung disease. Our results suggest that KL-6 could be a good biomarker to assess ILD severity in COVID-19 infection. Concerning the therapeutic response prediction, more studies are necessary.
Sections du résumé
BACKGROUND
BACKGROUND
Coronavirus disease COVID-19 has become a public health emergency of international concern. Together with the quest for an effective treatment, the question of the post-infectious evolution of affected patients in healing process remains uncertain. Krebs von den Lungen 6 (KL-6) is a high molecular weight mucin-like glycoprotein produced by type II pneumocytes and bronchial epithelial cells. Its production is raised during epithelial lesions and cellular regeneration. In COVID-19 infection, KL-6 serum levels could therefore be of interest for diagnosis, prognosis and therapeutic response evaluation.
MATERIALS AND METHODS
METHODS
Our study retrospectively compared KL-6 levels between a cohort of 83 COVID-19 infected patients and two other groups: healthy subjects (n = 70) on one hand, and a heterogenous group of patients suffering from interstitial lung diseases (n = 31; composed of 16 IPF, 4 sarcoidosis, 11 others) on the other hand. Demographical, clinical and laboratory indexes were collected. Our study aims to compare KL-6 levels between a COVID-19 population and healthy subjects or patients suffering from interstitial lung diseases (ILDs). Ultimately, we ought to determine whether KL-6 could be a marker of disease severity and bad prognosis.
RESULTS
RESULTS
Our results showed that serum KL-6 levels in COVID-19 patients were increased compared to healthy subjects, but to a lesser extent than in patients suffering from ILD. Increased levels of KL-6 in COVID-19 patients were associated with a more severe lung disease.
DISCUSSION AND CONCLUSION
CONCLUSIONS
Our results suggest that KL-6 could be a good biomarker to assess ILD severity in COVID-19 infection. Concerning the therapeutic response prediction, more studies are necessary.
Identifiants
pubmed: 33234132
doi: 10.1186/s12931-020-01560-4
pii: 10.1186/s12931-020-01560-4
pmc: PMC7683867
doi:
Substances chimiques
Biomarkers
0
MUC1 protein, human
0
Mucin-1
0
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
309Références
Chest. 2020 Aug;158(2):646-659
pubmed: 32268131
Respir Med. 2020 Jun;167:105981
pubmed: 32421546
J Virol. 2017 May 26;91(12):
pubmed: 28404843
Thorax. 2020 Feb;75(2):132-142
pubmed: 31801904
Lung. 2017 Jun;195(3):273-280
pubmed: 28353114
Pak J Med Sci. 2020 May;36(COVID19-S4):S6-S11
pubmed: 32582306
J Med Virol. 2020 Sep;92(9):1533-1541
pubmed: 32181903
Rheumatology (Oxford). 2019 Sep 1;58(9):1534-1546
pubmed: 31292645